Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31187428 | 1.00 | MEN1 (0.45) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL10301166 | 1.00 | MEN1 (0.45) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL31187424 | 1.00 | MEN1 (0.45) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL31187421 | 1.00 | MEN1 (0.45) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL63384 | 0.98 | TSHR (0.46) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL31348327 | 0.98 | TSHR (0.46) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL19039345 | 0.98 | TSHR (0.46) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL26921080 | 0.98 | TSHR (0.46) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL10301175 | 0.94 | MEN1 (0.41) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL16169883 | 0.94 | MEN1 (0.41) | MEN1KMT2ATHRBHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180028438-A1 | TOPICAL FORMULATION | LIMEWAY PHARMA DESIGN LIMITED (GB) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028438-A1 | TOPICAL FORMULATION | CERS2, SGMS1, SGMS2 | MEN1 1281/4885KMT2A 352/4885THRB 4170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.